Abstract
Six human β-galactoside α2,3-sialyltransferase genes, which are hST3Gal I-VI, have been cloned. Multiple genes encode enzymes with closely related catalytic specificities but different patterns of tissue expression. The multiple genes correspond to the control of various tissue specific regulators. Several studies have examined the transcriptional regulation of some human β-galactoside α2,3-sialyltransferases genes. Multiple mRNA forms differing only in the 5- untranslated regions have been identified in hST3Gal II, hST3Gal III, hST3Gal IV, hST3Gal V, and hST3Gal VI. These transcripts are produced by a combination of alternative splicing and promoter utilization, suggesting the transcriptional regulation of this gene depends on the use of alternative promoters, further suggesting that tissue-specific transcriptional regulation of these genes depends on the use of multiple genes and multiple promoters. The multiple regulatory pathways of these ubiquitous sialyltransferases may be differentially modulated in various cell types.
Keywords: Sialyltransferase, promoter, multiple gene, multiple promoter
Current Drug Targets
Title: Promoter Structure and Transcriptional Regulation of Human β-Galactoside α2, 3-Sialyltransferase Genes
Volume: 9 Issue: 4
Author(s): Akiyoshi Taniguchi
Affiliation:
Keywords: Sialyltransferase, promoter, multiple gene, multiple promoter
Abstract: Six human β-galactoside α2,3-sialyltransferase genes, which are hST3Gal I-VI, have been cloned. Multiple genes encode enzymes with closely related catalytic specificities but different patterns of tissue expression. The multiple genes correspond to the control of various tissue specific regulators. Several studies have examined the transcriptional regulation of some human β-galactoside α2,3-sialyltransferases genes. Multiple mRNA forms differing only in the 5- untranslated regions have been identified in hST3Gal II, hST3Gal III, hST3Gal IV, hST3Gal V, and hST3Gal VI. These transcripts are produced by a combination of alternative splicing and promoter utilization, suggesting the transcriptional regulation of this gene depends on the use of alternative promoters, further suggesting that tissue-specific transcriptional regulation of these genes depends on the use of multiple genes and multiple promoters. The multiple regulatory pathways of these ubiquitous sialyltransferases may be differentially modulated in various cell types.
Export Options
About this article
Cite this article as:
Taniguchi Akiyoshi, Promoter Structure and Transcriptional Regulation of Human β-Galactoside α2, 3-Sialyltransferase Genes, Current Drug Targets 2008; 9 (4) . https://dx.doi.org/10.2174/138945008783954998
DOI https://dx.doi.org/10.2174/138945008783954998 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Association Between Alcohol Use and the Progression of Alzheimer’s Disease
Current Alzheimer Research Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Pyrazolo[1,5-a]pyrimidines: A Close Look into their Synthesis and Applications
Current Organic Chemistry Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design Targeting the Progression of Parkinsons Disease
Current Neuropharmacology The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews Ultrasound Assisted Synthesis of 2-alkynyl Pyrazolo[1,5-a]pyrimidines as Potential Anti-cancer Agents
Letters in Drug Design & Discovery Nicotine, Body Weight and Potential Implications in the Treatment of Obesity
Current Topics in Medicinal Chemistry Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Towards Tyrosine Metabolism in Esophageal Squamous Cell Carcinoma
Combinatorial Chemistry & High Throughput Screening Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Imaging Drug Resistance with Radiolabeled Molecules
Current Pharmaceutical Design Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets Current Management of Neonatal Neuroblastoma
Current Pediatric Reviews Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Toxicity and Surface Modification of Dendrimers: A Critical Review
Current Drug Delivery Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets